MSP-2020 and MSP-2003, exhibiting a stronger and shorter acting psychedelic effect than psilocybin in preclinical testing, are selected for IND enabling studies MSP-2020 and MSP-2003, exhibiting a stronger and shorter acting psychedelic effect than psilocybin in preclinical testing, are selected for IND enabling studies
Mindset Pharma Selects Lead Clinical Candidates From “Family 2” of its Next Generation Psychedelic Drug Portfolio
Mindset Pharma Selects Lead Clinical Candidates From “Family 2” of its Next Generation Psychedelic Drug Portfolio -- MSP-2020 and MSP-2003, exhibiting a stronger and shorter acting psychedelic effect than psilocybin in preclinical testing, are selected for IND enabling studies MSP-2020 and MSP-2003, exhibiting a stronger and shorter acting psychedelic effect than psilocybin in preclinical testing, are selected for IND enabling studies